Hosted on MSN2mon
FDA Clears Spravato For Monotherapy Depression TreatmentsThe FDA granted approval to Spravato (esketamine) as the first monotherapy for adults with treatment-resistant depression, J&J said in a news release on Tuesday, Jan. 21. The decision came after a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback